Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

NCT04557956 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

NIH

Sponsor class

Conditions

Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Melanoma

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Computed Tomography
DRUG: Dabrafenib Mesylate
PROCEDURE: Echocardiography Test
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Multigated Acquisition Scan
DRUG: Tazemetostat Hydrobromide
DRUG: Trametinib Dimethyl Sulfoxide

Sponsor

National Cancer Institute (NCI)